Brandon Michael Henry: Interpreting Complement Activation After AAV Gene Therapy
Brandon Michael Henry, Chief Executive and Medical Officer at Aurelix Bio, shared a post on Linkedin about a recent article he and his colleague co-authored, published in Seminars in Thrombosis and Hemostasis, adding:
“Complement activation after AAV gene therapy is complex to interpret.
Early post-dose changes in platelets, C3/C4, or soluble C5b-9 do not automatically mean toxicity. In many cases, they may reflect expected pharmacodynamic engagement of innate immunity after vector exposure.
The clinical challenge is recognizing when that biology remains self-limited – and when it begins to evolve toward sustained complement amplification, endothelial injury, and thrombotic microangiopathy.
Our article in Seminars in Thrombosis and Hemostasis focuses on that interpretive boundary.
We provide a practical framework for integrating complement biomarkers with hematologic and renal markers, with emphasis on assay limitations, timing, trajectory, and clinical context.
The main point: gene therapy safety monitoring should not only ask whether complement activation is present.
It should ask what pattern it is following, whether it is resolving or escalating, and whether the broader clinical picture suggests expected biology or early vascular injury.”
Title: Laboratory Monitoring of Complement Activation in Gene Therapy: Analytical Pitfalls and Clinical Interpretation
Authors: Brandon M Henry, Melvin Y Rincon, Giuseppe Lippi, Zoltán Prohászka, Stefanie Benoit
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 29, 2026, 19:00Caitlin Raymond: Can Artificial Blood Solve Blood Supply Shortages?
-
Sep 29, 2026, 18:51Chaza Alaji: Dyslipidemia, Thrombosis and the DIC Diagnostic Trap
-
Sep 29, 2026, 17:31Rajnikant Patel: Bridging Ayurvedic Concepts and Modern Toxin-Mediated Disease
-
Sep 29, 2026, 17:13Nicholas Lang։ A Meaningful Case of Immune Thrombocytopenia
-
Sep 29, 2026, 16:55Ayatullah Gamal Wahab: When the CBC Lies
-
Sep 29, 2026, 16:35Jonathan Douxfils: Navigating the VTE Risk Continuum in Reproductive Medicine
-
Sep 29, 2026, 16:35Chaima Rajeh: Types of Anemia and Their Laboratory Features
-
Sep 29, 2026, 16:27Scott Isaacs: How GLP-1 RAs Target Systemic Inflammation to Drive Cardio, Autoimmune, and Gut Health
-
Sep 29, 2026, 16:21Yitshak Kreiss: From Treating Patients to Defining the Standard of Knowledge